Literature DB >> 30305377

Anti-NMDAR encephalitis complicating pregnancy.

Sabrina Kalam1, Aravindhan Baheerathan1, Cillian McNamara1, Victoria Singh-Curry2.   

Abstract

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis was first reported in 2005 in four patients with ovarian teratomas; there have been many further cases reported since the antigen for the NMDAR antibody was confirmed in 2007. Patients characteristically have a well-defined set of features, characterised by psychiatric disturbance, seizures and cognitive disturbance, followed by movement disorders, disorders of consciousness and dysautonomia. To date, 14 cases of NMDAR encephalitis have been described in the context of pregnancy. We report a case of NMDAR encephalitis in a 34-year-old woman at 8 weeks' gestation. She had a turbulent clinical course and was initially admitted to a psychiatric unit. She was successfully treated with first-line immunomodulatory therapies and surgical resection of an ovarian teratoma. Following discharge she delivered a healthy baby and made a complete clinical recovery. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  NMDA; epilepsy; neuroimmunology; obstetrics; psychiatry

Mesh:

Substances:

Year:  2018        PMID: 30305377     DOI: 10.1136/practneurol-2018-002042

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  2 in total

1.  Systemic lupus erythematosus associated with recurrent anti-NMDA receptor encephalitis during pregnancy.

Authors:  Shujiang Zhang; Yuan Yang; Ting Long; Zuoxiao Li
Journal:  Arch Womens Ment Health       Date:  2020-11-10       Impact factor: 3.633

2.  Pregnancy outcomes in anti-NMDA receptor encephalitis: Case series.

Authors:  Bastien Joubert; Anna García-Serra; Jesús Planagumà; Eugenia Martínez-Hernandez; Andrea Kraft; Frederick Palm; Takahiro Iizuka; Jérôme Honnorat; Frank Leypoldt; Francesc Graus; Josep Dalmau
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-01-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.